Xencor/XNCR

$18.38

-3%
-
1D1W1MYTD1YMAX

About Xencor

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Ticker

XNCR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bassil Dahiyat

Employees

280

Headquarters

Pasadena, United States
Website
xencor.com

Xencor Metrics

BasicAdvanced
$1.17B
Market cap
-
P/E ratio
-$2.10
EPS
0.79
Beta
-
Dividend rate
$1.17B
0.7948
$28.96
$16.49
704.03K
7.356
2.189
3.136
-14.04%
-18.06%
-15.3%
6.924
1.739
1.793
18.252
2.28%
-124.7%
11.12%

What the Analysts think about Xencor

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 12 analysts.
99.02% upside
High $59.00
Low $22.00
$18.38
Current price
$36.58
Average price target

Xencor Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-42.82% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$44.6M
-24.53%
Net income
$-19.1M
-21.07%
Profit margin
-42.82%
4.59%

Xencor Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 250.43%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.02
-$0.37
-$0.40
-$0.31
-
Expected
-$0.66
-$0.80
-$0.73
-$0.09
-$0.79
Surprise
53.88%
-53.59%
-44.94%
250.43%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Xencor stock?

Xencor (XNCR) has a market cap of $1.17B as of April 19, 2024.

What is the P/E ratio for Xencor stock?

The price to earnings (P/E) ratio for Xencor (XNCR) stock is 0 as of April 19, 2024.

Does Xencor stock pay dividends?

No, Xencor (XNCR) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Xencor dividend payment date?

Xencor (XNCR) stock does not pay dividends to its shareholders.

What is the beta indicator for Xencor?

Xencor (XNCR) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Xencor stock price target?

The target price for Xencor (XNCR) stock is $36.58, which is 99.02% above the current price of $18.38. This is an average based on projections from 12 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Xencor stock

Buy or sell Xencor stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing